Core Viewpoint - Koyuan Pharmaceutical announced the termination of its plan to issue shares for asset acquisition and related fundraising, withdrawing its application documents [1][2]. Group 1: Transaction Details - The company intended to acquire 99.42% of Shandong Hongjitang Pharmaceutical Group Co., Ltd. from 38 trading parties, including Linuo Investment Holding Group Co., Ltd. and Linuo Group Co., Ltd. [1][2]. - The transaction was valued at approximately 3.581 billion yuan, excluding the fundraising amount [2]. Group 2: Business Implications - The acquisition was expected to extend Koyuan Pharmaceutical's main business into traditional Chinese medicine and health products, enhancing operational efficiency and reducing costs [2]. - The company aimed to create a large-scale, well-known health platform in the pharmaceutical industry, improving its overall strength and value [2]. Group 3: Reason for Termination - The termination was due to changes in the overall market environment since the initial announcement of the transaction, leading to a decision made in the interest of all shareholders [2].